大分割放疗与常规分割放疗对新诊断胶质母细胞瘤的倾向性评分匹配分析
该研究纳入新诊断胶质母细胞瘤患者,比较常规分割放疗(CRT 60 Gy/30次)与大分割放疗(HFRT 60 Gy/15次)的疗效。经倾向性评分1:1匹配后每组82例,中位总生存期CRT组17.9个月、HFRT组16.7个月,1、2、3年总生存率两组相近(p=0.8),未见统计学显著差异。结论认为短程放疗的结局与CRT相当且负担更小。
要点
- 匹配后HFRT组与CRT组中位OS分别为16.7个月和17.9个月,差异无统计学意义(p=0.8)。
- 两组1、2、3年OS率分别为75.6%、33.3%、18.9%(HFRT)与75.6%、32.7%、15.5%(CRT)。
- 短程HFRT对预后差的患者负担更小,结局与CRT相当。
核心结论
- 短程大分割放疗在新诊断胶质母细胞瘤中结局与常规分割放疗相当,且对预后差的患者负担更小。
研究设计与样本
- 回顾性分析纳入新诊断胶质母细胞瘤患者,CRT为60 Gy/30次,HFRT为60 Gy/15次。
- 采用倾向性评分匹配(PSM), logistic回归纳入年龄、KPS、手术范围、MGMT和IDH状态。
- 共纳入267例,匹配前CRT组169例、HFRT组98例;1:1匹配后每组82例。
主要发现
- 匹配后CRT组中位OS为17.9个月,HFRT组为16.7个月。
- CRT组1、2、3年OS率分别为75.6%、32.7%、15.5%;HFRT组分别为75.6%、33.3%、18.9%(p=0.8)。
- 两种放疗方式之间未记录到统计学显著差异。
临床怎么用
- 对于新诊断胶质母细胞瘤患者,可考虑短程HFRT作为CRT的替代方案,尤其适合预后差、需减轻治疗负担者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The current treatment for newly diagnosed glioblastoma consists of surgery followed by conventional radiotherapy (CRT) with concomitant and adjuvant chemotherapy. Hypofractionated radiation therapy (HFRT) has been investigated and it resulted feasible and safe. The aim of this study was to evaluate whether HFRT can be comparable to CRT. MATERIALS AND METHODS: The analysis included newly diagnosed glioblastoma patients treated with CRT 60 Gy/30 fractions or HFRT 60 Gy/15 fractions. A propensity score matching analysis (PSM) was performed using a logistic regression that considered age, KPS, extent of surgery, MGMT and IDH status. RESULTS: A total of 267 patients were included; before PSM 169 were in CRT-group and 98 in HRFT-group. After 1:1 matching, 82 patients resulted in each group. The median OS time was 17.9 months for the CRT-group and 16.7 months for the HFRT-group; the 1, 2, 3-year OS rates were 75.6%, 32.7%, and 15.5% for the CRT-group, and 75.6%, 33.3%, and 18.9% for the HFRT-group (p value = 0.8). No statistically significant differences were recorded between the two radiation therapy treatments performed. CONCLUSIONS: A short course of radiation therapy would seem comparable to CRT in terms of outcome and less burdensome for these poor prognosis patients.
引用
- Navarria P, Pessina F, Franzese C, et al. Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. Radiother Oncol. 2017. PMID: 29291951. doi:10.1016/j.radonc.2017.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。